Employers Cutting GLP-1 Coverage as Costs Rise
A survey indicates that roughly 14% of U.S. employers have either stopped or intend to stop covering GLP-1 medications by 2027. The decision is driven by escalating health care expenses.
Related stories
Regeneron secures approval for ultra-rare bone disorder drug · Drug development
Large Employers See Health Care Costs Climb · Healthcare systems
AstraZeneca halts late-stage lung cancer trial; U.S. drug prices decline · Cancer research
Roche to invest $750M in Oregon manufacturing expansion · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: Pharmalittle: We’re reading about a GSK shingles shot, U.S. employers dropping GLP-1 coverage, and more.” Browse more stories.